Formycon
XTRA:FYB Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
WA
Consensus Narrative from 9 Analysts
Expected Launches Of Stelara And Keytruda Biosimilars Will Strengthen Future Pipeline
Key Takeaways The launch of biosimilars and strategic focus on high-growth areas indicate strong future revenue and earnings potential for Formycon. International expansion and commercial partnerships are expected to significantly boost Formycon's revenue by enhancing market share and distribution.
View narrative€87.22
FV
65.0% undervalued intrinsic discount49.08%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
23 days ago author updated this narrative